Parkwood LLC’s Revolution Medicines RVMD Stock Holding History

Parkwood LLC’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,845	Closed	-$227K	–	126
2024 Q2	$227K	Buy	+5,845	New	+$218K	0.03%	115

Other funds holding RVMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Parkwood LLC's RVMD Position: Q3 2024 in Review

Parkwood LLC sold out of Revolution Medicines (RVMD) in Q3 2024, closing a stake of 5,845 shares — an estimated $227K sold.

Parkwood LLC first reported a position in RVMD in Q2 2024 and held it in 1 quarter. The position peaked at $227K in Q2 2024. 255 funds tracked by Wall St. Rank hold RVMD as of Q3 2024.

Parkwood LLC reported no remaining Revolution Medicines position as of Q3 2024 after selling out during the quarter.
Parkwood LLC sold 5,845 Revolution Medicines shares in Q3 2024, an estimated $227K.
Parkwood LLC first reported a position in Revolution Medicines in Q2 2024 and held it in 1 quarter.
Parkwood LLC's Revolution Medicines position peaked at $227K in Q2 2024.
255 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2024.

Based on Parkwood LLC's 13F filing for Q3 2024, filed 14 Nov 2024.